Images List Premium Download Classic

Antagonist

Antagonist-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Self assembling nucleic acid nanostructures
Exicure, Inc.
June 22, 2017 - N°20170175121

Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of g-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of g-quadruplex stabilizing domains linked to the g-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as toll-like ...
Polypeptides, antibody variable domains and antagonists
Domantis Limited
June 22, 2017 - N°20170174775

The invention relates to anti-tnfr1 polypeptides and antibody single variable domains (dabs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dabs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the ...
Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
Merck Sharp & Dohme Corp.
June 22, 2017 - N°20170174773

The present disclosure describes combination therapies comprising an antagonist of programmed death 1 receptor (pd-1) and a selective 4-1 bb agonist, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express pd-l1.
Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Tlr7/8 antagonists and uses thereof
Merck Patent Gmbh
June 22, 2017 - N°20170174653

The present invention relates to compounds of formula i and pharmaceutically acceptable compositions thereof, useful as tlr7/8 antagonists.
Devices, systems and methods for cell modification
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
June 22, 2017 - N°20170173254

A method of modifying cells includes removing fluid including cells from a patient, contacting the removed fluid from the patient with at least one surface upon which at least one agent to interact at least one cell receptor is immobilized to modify cells in the fluid, and returning the fluid to the patient. The agent can, for example, be immobilized ...
Compositions and methods to treat addiction
The United States Government Represented By The Department Of Veterans Affairs
June 22, 2017 - N°20170173039

The present invention provides compositions and methods comprising talampanel and/or perampanel for treating or preventing an addictive disease or disorder, such as alcoholism, in a subject in need thereof. Ampa receptor (ampa-rs) antagonists (i. E., blockers), such as perampanel and talampanel, reduce drug and alcohol seeking behaviors in mammals since activation of glutamatergic ampa receptors promotes addictive behaviors in ...
Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method and device for automatic identification of an opioid overdose and injection of an opioid ...
Hoffmann-la Roche Inc.
June 22, 2017 - N°20170172522

A method for detecting the need for providing assistance to an individual suspected of overdosing on an opiate is provided. The method includes using a wearable device for continuous or intermittent monitoring of one or more physiological parameters of the individual. If the level of one of the one or more physiological parameters exceeds a threshold level specific to that ...
Secreted proteins
Incyte Corporation
June 15, 2017 - N°20170166888

The invention provides human secreted proteins (secp) and polynucleotides which identify and encode secp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of secp.
Immunological reagents
Mabquest Sa
June 15, 2017 - N°20170166642

This disclosure relates to binding agents with specificity for programmed cell death 1 (pd-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e. G., human immunodeficiency virus (hiv)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“p2”) on pd-1 that is linked with a ...
Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
Merck Sharp & Dohme Corp.
June 15, 2017 - N°20170166641

The present disclosure describes combination therapies comprising an antagonist of programmed death 1 receptor (pd-1) and a vegfr inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express pd-l1.
Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
Oncomed Pharmaceuticals, Inc.
June 15, 2017 - N°20170166632

Methods for treating cancer comprising administering a dll4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a dll4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
Therapeutic agent for solid cancer
The University Of Tokyo
June 15, 2017 - N°20170165364

Disclosed is a novel means effective for treatment, metastasis-inhibition, and recurrence-inhibition of human solid cancer. A therapeutic agent for solid cancer according to the present invention comprises as an effective ingredient an anti-cd4 antibody having a high cytotoxic activity, or an anti-cd4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. Said anti-cd4 antibody ...
Pharmaceutical composition for treating or preventing sensorineural hearing loss, containing cysteinyl leukotriene receptor antagonist and ...
Ajou University Industry-academic Cooperation Foundation
June 15, 2017 - N°20170165309

The present invention provides a compound having an effect of preventing and/or treating the damage or degeneration of cochlear (and vestibular) mother cells and spiral ganglion neurons by downregulating a cysteinyl leukotriene receptor. Particularly, the present invention provides a composition for preventing or treating sensorineural hearing loss, containing a cysteinyl leukotriene receptor and a ginkgo biloba extract as active ...
Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for modulation of rorgammat functions
Ajou University Industry-academic Cooperation Foundation
June 08, 2017 - N°20170159057

The present invention relates to expression of rorγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of il17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the ...
Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
University Of Southampton
June 08, 2017 - N°20170158771

Through a combination of in vitro and in vivo approaches, the inventors show that human igg2 (h2) delivers unique fcγr-independent agonistic activity to anti-cd40 antibodies and to antibodies specific to other immunostimulatory receptors, including 4-1bb and cd28. Investigation of an anti-human cd40 mab, lob7. 4, revealed that the unique activity of h2 was dependent upon the precise ...
Caninized anti-ngf antibodies and methods thereof
Zoetis Services Llc
June 08, 2017 - N°20170158756

The invention provides novel caninized anti-ngf antibodies (such as caninized anti-ngf antagonist antibodies and antigen binding proteins), and polynucleotides encoding the same. The invention further provides use of said antibodies or antigen binding proteins and/or nucleotides in the treatment and/or prevention of ngf related disorders, particularly pain.
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
Chiesi Farmaceutici S.p.a.
June 08, 2017 - N°20170158694

Compounds of formula (i), defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
Process for preparation of androgen receptor antagonist
Cadila Healthcare Limited
June 08, 2017 - N°20170158643

The present invention provides an isopropanol solvate of enzalutamide. The present invention also provides a process for the preparation of androgen receptor antagonist. In particular, the present invention provides a process for the preparation of enzalutamide or its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof.
Biomarkers useful in the treatment of il-23a related diseases
Boehringer Ingelheim International Gmbh
June 08, 2017 - N°20170157246

This invention generally relates to biomarkers useful in the treatment of il-23 related diseases, in particular inflammatory diseases such as psoriasis. The invention also relates to methods of using the biomarkers disclosed herein, for example in therapies utilizing il-23 antagonists.
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule ...
Jomoco, Corp.
June 08, 2017 - N°20170157215

Methods and compositions for preventing an immune response to an immunogenic therapeutic agent [i. E. Anti-drug antibody (ada), a. K. A. Anti-therapeutic antibody (ata)] are disclosed. One of the disclosed methods comprises administering an effective amount of an immunosuppressant such as an il-2 signaling pathway inhibitor, including an antagonist, super agonist or partial agonist to the cytokine il-2, to the ...
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
Purdue Pharmaceuticals L.p.
June 08, 2017 - N°20170157115

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized ...
Loading